Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes
Completed
This trial is conducted in Europe and North and South America. The aim of the trial is to investigate the efficacy and safety of semaglutide once-weekly versus exenatide ER (extended release) 2.0 mg once-weekly as add-on to 1-2 oral antidiabetic drugs (OADs) in subjects with type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2019
Locations: Novo Nordisk Investigational Site, Albuquerque, New Mexico
Conditions: Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes
Completed
This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of semaglutide once-weekly versus placebo in drug-naïve subjects with type 2 diabetes. (SUSTAIN™ 1-Monotherapy).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2019
Locations: Novo Nordisk Investigational Site, Albuquerque, New Mexico
Conditions: Diabetes, Diabetes Mellitus, Type 2